These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 14682272)

  • 1. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.
    Feinberg J
    AIDS Clin Care; 2003 Nov; 15(11):94. PubMed ID: 14682272
    [No Abstract]   [Full Text] [Related]  

  • 2. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Exploring once-daily tenofovir + 3TC + abacavir: an argument for clinical-trials-based data.
    Becker S; Feinberg J
    AIDS Clin Care; 2003 Sep; 15(9):81. PubMed ID: 14669727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viread, Epivir and Ziagen combination: failure in naïve patients with a once-daily regimen.
    Berger DS
    Posit Aware; 2003; 14(5):51-2. PubMed ID: 14679946
    [No Abstract]   [Full Text] [Related]  

  • 4. Failure of combination abacavir + tenofovir + lamivudine (3TC).
    AIDS Treat News; 2003 Jul; (393):2. PubMed ID: 14679923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.
    Khanlou H; Farthing C
    AIDS Patient Care STDS; 2006 Sep; 20(9):604-5. PubMed ID: 16987045
    [No Abstract]   [Full Text] [Related]  

  • 6. Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
    Albrecht H
    AIDS Clin Care; 2008 Apr; 20(4):28. PubMed ID: 19271262
    [No Abstract]   [Full Text] [Related]  

  • 7. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple combinations regimens for HIV.
    Lancet Infect Dis; 2003 Nov; 3(11):682. PubMed ID: 14603888
    [No Abstract]   [Full Text] [Related]  

  • 9. Failure of tenofovir + abacavir + 3TC combination; full report published, more insight.
    James JS
    AIDS Treat News; 2005; (416):5-6. PubMed ID: 16388545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early nonresponse for tenofovir regimen.
    AIDS Patient Care STDS; 2003 Nov; 17(11):603. PubMed ID: 14748354
    [No Abstract]   [Full Text] [Related]  

  • 11. Investigating new antiretroviral combinations.
    Carr A
    J Infect Dis; 2006 Jun; 193(12):1742; author reply 1742-3. PubMed ID: 16703520
    [No Abstract]   [Full Text] [Related]  

  • 12. Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study.
    Elion R; Cohen C; DeJesus E; Redfield R; Gathe J; Hsu R; Yau L; Ross L; Ha B; Lanier RE; Scott T;
    HIV Clin Trials; 2006; 7(6):324-33. PubMed ID: 17208898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
    Kuritzkes DR
    J Infect Dis; 2005 Dec; 192(11):1867-8. PubMed ID: 16267755
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-HIV agents. Low rate of early virologic failure seen with a combination of Trizivir and tenofovir.
    TreatmentUpdate; 2004 Mar; 16(2):2-3. PubMed ID: 17219666
    [No Abstract]   [Full Text] [Related]  

  • 15. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
    Bayonne Kombo ES; Gathse A
    Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
    [No Abstract]   [Full Text] [Related]  

  • 16. Tenofovir disoproxil fumarate.
    Antoniou T
    Drugs; 2003; 63(15):1609-10. PubMed ID: 12887266
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus.
    Ristig M; Drechsler H; Crippin J; Lisker-Melman M; Tebas P
    AIDS Patient Care STDS; 2003 Sep; 17(9):439-42. PubMed ID: 14588080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
    J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
    Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D;
    Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abacavir arm stopped in clinical trial.
    James JS
    AIDS Treat News; 2003 Apr; (390):6-7. PubMed ID: 12739475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.